Tailoring Type II Diabetes Treatment: Investigating the Effect of 5-HTT Polymorphisms on HbA1c Levels after Metformin Initiation
Aims. To investigate the effect of serotonin transporter (5-HTT) polymorphisms on change in HbA1c levels six months after metformin initiation in type 2 diabetes patients. Materials and Methods. Participants of PROVALID (PROspective cohort study in patients with type 2 diabetes mellitus for VALidati...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Hindawi Limited
2024-01-01
|
| Series: | Journal of Diabetes Research |
| Online Access: | http://dx.doi.org/10.1155/2024/7922486 |
| _version_ | 1797339308305154048 |
|---|---|
| author | Taichi Ochi Stijn de Vos Daan Touw Petra Denig Talitha Feenstra Eelko Hak |
| author_facet | Taichi Ochi Stijn de Vos Daan Touw Petra Denig Talitha Feenstra Eelko Hak |
| author_sort | Taichi Ochi |
| collection | DOAJ |
| description | Aims. To investigate the effect of serotonin transporter (5-HTT) polymorphisms on change in HbA1c levels six months after metformin initiation in type 2 diabetes patients. Materials and Methods. Participants of PROVALID (PROspective cohort study in patients with type 2 diabetes mellitus for VALidation of biomarkers) within the GIANTT (Groningen Initiative to ANalyse Type 2 Diabetes Treatment) cohort who initiated metformin were genotyped for combined 5-HTTLPR/rs25531 (L∗L∗, L∗S∗, and S∗S∗) and 5-HTT VNTR (STin 2.12, 12/-, and 10/-) polymorphisms, respectively. Multiple linear regression was applied to determine the change in HbA1c level from baseline date to six months across 5-HTTLPR/VNTR genotype groups, adjusted for baseline HbA1c, age, gender, triglyceride level, low-density lipoprotein level, and serum creatinine. Results. 157 participants were included, of which 56.2% were male. The average age was 59.3±9.23 years, and the mean baseline HbA1c was 7.49%±1.21%. 5-HTTLPR was characterized in 46 patients as L∗L∗, 70 patients as L∗S∗, and 41 patients as S∗S∗ genotypes. No significant association was found between 5-HTTLPR and 5-HTT VNTR genotypes and change in HbA1c after adjustments. Conclusions. 5-HTT polymorphisms did not affect HbA1c levels six months after the start of metformin. Further long-term studies in large samples would be relevant to determine which polymorphisms can explain the variation in response to metformin treatment. |
| first_indexed | 2024-03-08T09:44:08Z |
| format | Article |
| id | doaj.art-d9b8afe506f24094b9bfb4bae02b6973 |
| institution | Directory Open Access Journal |
| issn | 2314-6753 |
| language | English |
| last_indexed | 2024-03-08T09:44:08Z |
| publishDate | 2024-01-01 |
| publisher | Hindawi Limited |
| record_format | Article |
| series | Journal of Diabetes Research |
| spelling | doaj.art-d9b8afe506f24094b9bfb4bae02b69732024-01-30T00:00:11ZengHindawi LimitedJournal of Diabetes Research2314-67532024-01-01202410.1155/2024/7922486Tailoring Type II Diabetes Treatment: Investigating the Effect of 5-HTT Polymorphisms on HbA1c Levels after Metformin InitiationTaichi Ochi0Stijn de Vos1Daan Touw2Petra Denig3Talitha Feenstra4Eelko Hak5Groningen Research Institute of PharmacyGroningen Research Institute of PharmacyDepartment of Clinical Pharmacy and PharmacologyDepartment of Clinical Pharmacy and PharmacologyGroningen Research Institute of PharmacyGroningen Research Institute of PharmacyAims. To investigate the effect of serotonin transporter (5-HTT) polymorphisms on change in HbA1c levels six months after metformin initiation in type 2 diabetes patients. Materials and Methods. Participants of PROVALID (PROspective cohort study in patients with type 2 diabetes mellitus for VALidation of biomarkers) within the GIANTT (Groningen Initiative to ANalyse Type 2 Diabetes Treatment) cohort who initiated metformin were genotyped for combined 5-HTTLPR/rs25531 (L∗L∗, L∗S∗, and S∗S∗) and 5-HTT VNTR (STin 2.12, 12/-, and 10/-) polymorphisms, respectively. Multiple linear regression was applied to determine the change in HbA1c level from baseline date to six months across 5-HTTLPR/VNTR genotype groups, adjusted for baseline HbA1c, age, gender, triglyceride level, low-density lipoprotein level, and serum creatinine. Results. 157 participants were included, of which 56.2% were male. The average age was 59.3±9.23 years, and the mean baseline HbA1c was 7.49%±1.21%. 5-HTTLPR was characterized in 46 patients as L∗L∗, 70 patients as L∗S∗, and 41 patients as S∗S∗ genotypes. No significant association was found between 5-HTTLPR and 5-HTT VNTR genotypes and change in HbA1c after adjustments. Conclusions. 5-HTT polymorphisms did not affect HbA1c levels six months after the start of metformin. Further long-term studies in large samples would be relevant to determine which polymorphisms can explain the variation in response to metformin treatment.http://dx.doi.org/10.1155/2024/7922486 |
| spellingShingle | Taichi Ochi Stijn de Vos Daan Touw Petra Denig Talitha Feenstra Eelko Hak Tailoring Type II Diabetes Treatment: Investigating the Effect of 5-HTT Polymorphisms on HbA1c Levels after Metformin Initiation Journal of Diabetes Research |
| title | Tailoring Type II Diabetes Treatment: Investigating the Effect of 5-HTT Polymorphisms on HbA1c Levels after Metformin Initiation |
| title_full | Tailoring Type II Diabetes Treatment: Investigating the Effect of 5-HTT Polymorphisms on HbA1c Levels after Metformin Initiation |
| title_fullStr | Tailoring Type II Diabetes Treatment: Investigating the Effect of 5-HTT Polymorphisms on HbA1c Levels after Metformin Initiation |
| title_full_unstemmed | Tailoring Type II Diabetes Treatment: Investigating the Effect of 5-HTT Polymorphisms on HbA1c Levels after Metformin Initiation |
| title_short | Tailoring Type II Diabetes Treatment: Investigating the Effect of 5-HTT Polymorphisms on HbA1c Levels after Metformin Initiation |
| title_sort | tailoring type ii diabetes treatment investigating the effect of 5 htt polymorphisms on hba1c levels after metformin initiation |
| url | http://dx.doi.org/10.1155/2024/7922486 |
| work_keys_str_mv | AT taichiochi tailoringtypeiidiabetestreatmentinvestigatingtheeffectof5httpolymorphismsonhba1clevelsaftermetformininitiation AT stijndevos tailoringtypeiidiabetestreatmentinvestigatingtheeffectof5httpolymorphismsonhba1clevelsaftermetformininitiation AT daantouw tailoringtypeiidiabetestreatmentinvestigatingtheeffectof5httpolymorphismsonhba1clevelsaftermetformininitiation AT petradenig tailoringtypeiidiabetestreatmentinvestigatingtheeffectof5httpolymorphismsonhba1clevelsaftermetformininitiation AT talithafeenstra tailoringtypeiidiabetestreatmentinvestigatingtheeffectof5httpolymorphismsonhba1clevelsaftermetformininitiation AT eelkohak tailoringtypeiidiabetestreatmentinvestigatingtheeffectof5httpolymorphismsonhba1clevelsaftermetformininitiation |